GR3032777T3 - Cntf family antagonists - Google Patents
Cntf family antagonistsInfo
- Publication number
- GR3032777T3 GR3032777T3 GR20000400479T GR20000400479T GR3032777T3 GR 3032777 T3 GR3032777 T3 GR 3032777T3 GR 20000400479 T GR20000400479 T GR 20000400479T GR 20000400479 T GR20000400479 T GR 20000400479T GR 3032777 T3 GR3032777 T3 GR 3032777T3
- Authority
- GR
- Greece
- Prior art keywords
- cntf
- family antagonists
- cntf family
- receptor component
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/140,222 US5470952A (en) | 1993-10-20 | 1993-10-20 | CNTF and IL-6 antagonists |
PCT/US1994/011873 WO1995011303A1 (en) | 1993-10-20 | 1994-10-19 | Cntf family antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
GR3032777T3 true GR3032777T3 (en) | 2000-06-30 |
Family
ID=22490270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR20000400479T GR3032777T3 (en) | 1993-10-20 | 2000-02-28 | Cntf family antagonists |
Country Status (16)
Country | Link |
---|---|
US (2) | US5470952A (el) |
EP (1) | EP0726954B2 (el) |
JP (1) | JP3961562B2 (el) |
CN (1) | CN1138350A (el) |
AT (1) | ATE187982T1 (el) |
AU (1) | AU679579B2 (el) |
CA (1) | CA2173846C (el) |
DE (1) | DE69422304T3 (el) |
DK (1) | DK0726954T4 (el) |
ES (1) | ES2139759T5 (el) |
GR (1) | GR3032777T3 (el) |
HK (1) | HK1008346A1 (el) |
IL (1) | IL111324A0 (el) |
PT (1) | PT726954E (el) |
WO (1) | WO1995011303A1 (el) |
ZA (1) | ZA948242B (el) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728536A (en) * | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
CA2147466A1 (en) * | 1992-10-20 | 1994-04-28 | Just P. J. Brakenhoff | Interleukin-6 receptor antagonists |
IT1261787B (it) * | 1993-06-23 | 1996-06-03 | Angeletti P Ist Richerche Bio | Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130. |
US5470952A (en) * | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
AUPN024994A0 (en) * | 1994-12-23 | 1995-01-27 | Ludwig Institute For Cancer Research | Assay and peptides for use therein |
US7070783B1 (en) * | 1995-05-09 | 2006-07-04 | The Mathilda And Terence Kennedy Institute Of Rheumatology | Small molecular weight TNF receptor multimeric molecule |
US6217858B1 (en) * | 1997-02-11 | 2001-04-17 | Hadasit & Medical Research Services & Development Company, Ltd. | Pharmaceutical composition for treating hepatitis B virus (HBV) infection |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
AU3668897A (en) * | 1996-07-17 | 1998-02-09 | University Of Medicine And Dentistry Of New Jersey | Chimeric receptors for jak-stat signal transduction |
GB9621095D0 (en) * | 1996-10-09 | 1996-11-27 | Imperial College | Novel system |
IT1288388B1 (it) | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
US6046158A (en) * | 1996-12-20 | 2000-04-04 | Board Of Regents The University Of Texas Systems | Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof |
SE9701010D0 (sv) | 1997-03-19 | 1997-03-19 | Pharmacia & Upjohn Ab | Antibody |
EP2322216A1 (en) | 1997-03-21 | 2011-05-18 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient |
WO1999037772A1 (en) | 1998-01-23 | 1999-07-29 | Immunex Corporation | Il-18 receptors |
US6410245B1 (en) * | 1998-04-01 | 2002-06-25 | Affymax, Inc. | Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions |
US6927044B2 (en) * | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
US7083949B2 (en) * | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
US6864359B1 (en) * | 1999-02-11 | 2005-03-08 | Xencor | Structure-based screening techniques for drug discovery |
ATE420894T1 (de) * | 1999-03-11 | 2009-01-15 | Schering Corp | Cytokine aus säugetieren, verwandte reagenzien und verfahren |
US6800460B1 (en) | 1999-03-11 | 2004-10-05 | Schering Corporation | Mammalian cytokine complexes |
US6673771B1 (en) | 1999-07-28 | 2004-01-06 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting osteoclast activity |
US6682739B1 (en) * | 1999-07-28 | 2004-01-27 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting osteoclastogenesis |
JP2003505514A (ja) * | 1999-07-28 | 2003-02-12 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア | 破骨細胞生成を阻害する方法 |
AU7078200A (en) | 1999-08-27 | 2001-03-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use |
AR025984A1 (es) * | 1999-10-07 | 2002-12-26 | Maxygen Aps | Polipeptidos oligomericos de cadena simple |
WO2002064021A2 (en) * | 2001-02-12 | 2002-08-22 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of ciliary neurotrophic factor activity |
US6864047B2 (en) * | 2001-03-29 | 2005-03-08 | Mayo Foundation For Medical Education And Research | IL1-β: a new target for myeloma therapy |
EP1382965B1 (en) * | 2001-04-23 | 2005-11-30 | Eiken Kagaku Kabushiki Kaisha | Analysis method using reporter (label) intermolecular interaction |
DK1385882T3 (da) | 2001-05-11 | 2008-02-11 | Amgen Inc | Peptider og relaterede molekyler, der binder til TALL-1 |
US20030125251A1 (en) * | 2001-06-21 | 2003-07-03 | Wakefield Lalage M. | Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta |
KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
JP2005514913A (ja) * | 2001-08-22 | 2005-05-26 | へリックス バイオファーマ コーポレイション | 内在性タンパク質の発現、精製および検出のための、方法およびデバイス |
JP2005516001A (ja) | 2001-12-05 | 2005-06-02 | ベイラー カレッジ オブ メディスン | 交感神経活動状態の調節による骨形成の制御のための方法及び組成物 |
AU2003259995B2 (en) | 2002-08-28 | 2009-07-02 | Immunex Corporation | Compositions and methods for treating cardiovascular disease |
US20060057145A1 (en) * | 2002-10-25 | 2006-03-16 | Government Of The United States Of America As Represented By The Secretary, Dept. Of Health | Methods to prevent tumor recurrence by blockade of tgf-beta |
FI20031050A (fi) * | 2003-07-09 | 2005-01-10 | Valtion Teknillinen | Menetelmä proteiinien katkaisuun |
WO2005033137A1 (en) * | 2003-09-30 | 2005-04-14 | Regeneron Pharmaceuticals, Inc. | Modified ciliary neurotrophic factor polypeptides with reduced antigenicity |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
EP1682584B1 (en) | 2003-11-13 | 2013-04-17 | Hanmi Science Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
US20050244472A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
US8591885B2 (en) | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
US7786261B2 (en) * | 2004-09-02 | 2010-08-31 | National Research Council Of Canada | Coiled-coil fusion proteins comprising cell receptor domains |
CA2598090A1 (en) * | 2005-02-17 | 2006-08-24 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Synergistic effect of tgf-beta blockade and immunogenic agents on tumors |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
US7889347B2 (en) | 2005-11-21 | 2011-02-15 | Plexera Llc | Surface plasmon resonance spectrometer with an actuator driven angle scanning mechanism |
US7463358B2 (en) | 2005-12-06 | 2008-12-09 | Lumera Corporation | Highly stable surface plasmon resonance plates, microarrays, and methods |
AU2006332533A1 (en) * | 2005-12-30 | 2007-07-12 | Pharmaessentia Corp. | Drug-polymer conjugates |
AU2007272970C1 (en) | 2006-07-11 | 2013-01-10 | Roy C. Levitt | Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors |
CA3177366A1 (en) | 2006-08-10 | 2008-02-21 | Roy C. Levitt | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
WO2008113185A1 (en) * | 2007-03-19 | 2008-09-25 | National Research Counsil Of Canada | Antagonists of ligands and uses thereof |
US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
US8004669B1 (en) | 2007-12-18 | 2011-08-23 | Plexera Llc | SPR apparatus with a high performance fluid delivery system |
EP2326670A4 (en) * | 2008-09-17 | 2014-04-16 | Nat Res Council Canada | HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY |
ES2879430T3 (es) | 2012-11-15 | 2021-11-22 | Apellis Pharmaceuticals Inc | Análogos de compstatina de acción prolongada y composiciones y métodos relacionados |
WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
JP2016528295A (ja) | 2013-08-22 | 2016-09-15 | アクセルロン ファーマ, インコーポレイテッド | Tgf−ベータ受容体ii型変異体およびその使用 |
JP7320350B2 (ja) | 2015-08-04 | 2023-08-03 | アクセルロン ファーマ インコーポレイテッド | 骨髄増殖性障害を処置するための方法 |
ES2974107T3 (es) | 2015-10-07 | 2024-06-25 | Apellis Pharmaceuticals Inc | Regímenes de dosificación |
JP2020516607A (ja) | 2017-04-07 | 2020-06-11 | アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals,Inc. | 投与レジメンならびに関連組成物および方法 |
BR112019021812A2 (pt) | 2017-04-21 | 2020-05-26 | Kindred Biosciences, Inc. | Molécula receptora de il4/il13 para uso veterinário |
PL3628049T3 (pl) | 2017-05-04 | 2023-09-25 | Acceleron Pharma Inc. | Białka fuzyjne receptora TGF-beta typu II i ich zastosowania |
EA202091710A1 (ru) | 2018-03-09 | 2021-02-16 | Агенус Инк. | Антитела против cd73 и способы их применения |
EP3836954A1 (en) | 2018-08-13 | 2021-06-23 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU643427B2 (en) * | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
US5262522A (en) * | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
JP3255699B2 (ja) * | 1992-04-23 | 2002-02-12 | 味の素株式会社 | ヒトIL−2レセプターγ鎖分子 |
US5470952A (en) * | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
-
1993
- 1993-10-20 US US08/140,222 patent/US5470952A/en not_active Expired - Lifetime
-
1994
- 1994-10-18 IL IL11132494A patent/IL111324A0/xx unknown
- 1994-10-19 CN CN94194575A patent/CN1138350A/zh active Pending
- 1994-10-19 WO PCT/US1994/011873 patent/WO1995011303A1/en active IP Right Grant
- 1994-10-19 PT PT94930818T patent/PT726954E/pt unknown
- 1994-10-19 EP EP94930818A patent/EP0726954B2/en not_active Expired - Lifetime
- 1994-10-19 DE DE69422304T patent/DE69422304T3/de not_active Expired - Lifetime
- 1994-10-19 ES ES94930818T patent/ES2139759T5/es not_active Expired - Lifetime
- 1994-10-19 JP JP51216995A patent/JP3961562B2/ja not_active Expired - Fee Related
- 1994-10-19 AU AU79827/94A patent/AU679579B2/en not_active Ceased
- 1994-10-19 CA CA002173846A patent/CA2173846C/en not_active Expired - Fee Related
- 1994-10-19 AT AT94930818T patent/ATE187982T1/de active
- 1994-10-19 DK DK94930818T patent/DK0726954T4/da active
- 1994-10-20 ZA ZA948242A patent/ZA948242B/xx unknown
-
1995
- 1995-11-27 US US08/563,105 patent/US5844099A/en not_active Expired - Lifetime
-
1998
- 1998-07-15 HK HK98109176A patent/HK1008346A1/xx not_active IP Right Cessation
-
2000
- 2000-02-28 GR GR20000400479T patent/GR3032777T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
ZA948242B (en) | 1995-06-13 |
AU679579B2 (en) | 1997-07-03 |
US5844099A (en) | 1998-12-01 |
IL111324A0 (en) | 1994-12-29 |
AU7982794A (en) | 1995-05-08 |
EP0726954B1 (en) | 1999-12-22 |
CN1138350A (zh) | 1996-12-18 |
DE69422304T3 (de) | 2007-12-27 |
EP0726954A1 (en) | 1996-08-21 |
DK0726954T3 (da) | 2000-05-01 |
PT726954E (pt) | 2000-04-28 |
JP3961562B2 (ja) | 2007-08-22 |
CA2173846C (en) | 2009-01-27 |
DE69422304D1 (de) | 2000-01-27 |
HK1008346A1 (en) | 1999-05-07 |
EP0726954B2 (en) | 2007-05-30 |
DK0726954T4 (da) | 2007-10-01 |
JPH09504030A (ja) | 1997-04-22 |
WO1995011303A1 (en) | 1995-04-27 |
ES2139759T3 (es) | 2000-02-16 |
US5470952A (en) | 1995-11-28 |
DE69422304T2 (de) | 2000-05-11 |
ES2139759T5 (es) | 2007-11-16 |
CA2173846A1 (en) | 1995-04-27 |
ATE187982T1 (de) | 2000-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR3032777T3 (en) | Cntf family antagonists | |
ATE309375T1 (de) | Onkostatin- m rezeptor | |
AU3659897A (en) | Chemokine receptor antagonists and methods of use therefor | |
ATE401404T1 (de) | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie | |
NO952398L (no) | Pyrrolpyrimidiner som CRF antagonister | |
AU4422293A (en) | Substituted 2-amidotetralins as melatonin agonists and antagonists | |
ES2164054T3 (es) | Antagonistas de receptores de endotelina. | |
AU5194496A (en) | 5-HT4 receptor antagonists | |
ZA964744B (en) | Crf receptor antagonists and methods relating thereto | |
ES2172535T3 (es) | Antagonistas de los receptores de la endotelina. | |
GR1001129B (el) | Ανταγωνιστες ccκ αναλογου αμινοξεος. | |
SI0736525T1 (en) | Benzonitriles as 5-HT agonists and antagonists | |
EP0488959A3 (en) | New uses of competitive nmda receptor antagonists | |
PL310386A1 (en) | Antagonists of factor i receptors | |
IT8848075A0 (it) | Anello di regolazione adatto all'uso di frizioni con compensazione dell'usura manuali e automatiche | |
ZA952461B (en) | Antagonists of endothelin receptors | |
ES2140489T3 (es) | Receptor de interferona soluble, su preparacion y su uso. | |
ES2171196T3 (es) | Uso de antagonistas del receptor cck-b para el tratamiento de trastornos del sueño. | |
IL118299A0 (en) | Pharmacological use of AII-receptor antagonists | |
AU9064191A (en) | Use of angiotensin ii receptor antagonists in the treatment of atheroma | |
HK1032355A1 (en) | Endothelin antagonist and beta receptor blocking agent as combined preparations. | |
BG101849A (en) | Bicyclic tachyquinine antagonists, their preparation and use in pharmaceutical compositions | |
MX9203778A (es) | Antagonistas del receptor &-adrenergico y metodos de uso de los mismos. | |
AU3769089A (en) | Alpha-adrenergic receptor antagonists | |
SG67345A1 (en) | Sesquiterpenes their preparation and their use as inhibitors acting on the gaba-benzodiazepine receptor |